Since Alzheimer disease (AD) is a multifactorial disease, recent therapeutical approaches concentrate on the
development of a multitargeting drug. Various protein kinases are known to be involved in the progression of AD. A first
series of 3-ethoxycarbonyl-1-aza-9-oxafluorenes has been synthesized and biologically evaluated as AD-relevant protein
kinase inhibitors. A concentration-dependent inhibition of important AD-relevant kinases has been characterized after the
selectivity of kinase inhibition had been demonstrated. Structure-activity relationships of protein kinase inhibition are discussed
and first multitargeting inhibitors have been identified.
Keywords: Multitargeting, structure-activity relationships, biological activity, alzheimer disease, compound profiling, protein
Rights & PermissionsPrintExport